Trifluridine/Tipiracil Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 15 mg/6.14 mg , 20 mg / 8.19 mg
Reference Brands: Lonsurf (USA)
Category:
Oncology Cancer Care
Trifluridine/Tipiracil is available in Tablets
and strengths such as 15 mg/6.14 mg , 20 mg / 8.19 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Trifluridine/Tipiracil is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Trifluridine/Tipiracil can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lonsurf, a combination of trifluridine and tipiracil, is a fixed-dose oral medication used as a third- or fourth-line treatment for metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have previously undergone chemotherapy and targeted therapies. Trifluridine, a nucleoside analog, incorporates into tumor DNA, disrupting DNA synthesis and inhibiting cancer cell proliferation. Tipiracil, a thymidine phosphorylase inhibitor, prevents the rapid breakdown of trifluridine, enhancing its bioavailability and therapeutic effectiveness.
By combining these two agents, Lonsurf provides a targeted approach to slow tumor growth in patients with advanced cancer who have limited treatment options. It is administered orally in tablet form and is dosed according to body surface area and treatment cycles. Lonsurf’s mechanism ensures that trifluridine remains active long enough to exert cytotoxic effects on tumor cells while minimizing systemic exposure and toxicity. Approved in multiple regulated markets including the USA, EU, and UK, Lonsurf has become a vital therapy for patients with metastatic colorectal and gastric cancers, offering an important option when standard chemotherapy and biologic therapies have been exhausted.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing